| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

6 July 2020

ORYZON presents final data from its Phase IIa clinical trial REIMAGINE at the 28th European Congress of Psychiatry, EPA 2020

28 July 2020

Epigenetic Therapeutic Targets Summit 2020

27-31 July 2020

Alzheimer's Association International Conference, AAIC 2020

4-7 July 2020

28th European Congress of Psychiatry, EPA 2020

2 July 2020

ORYZON to present at upcoming virtual international conferences

25 June 2020

ORYZON raises its share capital

19 June 2020

ORYZON enters into pioneering precision medicine collaboration with La Paz Hospital in Madrid for Phelan-McDermid Syndrome

15 June 2020

ORYZON initiates a new project to explore the efficacy of vafidemstat in the treatment of schizophrenia

12 June 2020

ORYZON presents new Phase II iadademstat efficacy data in AML at EHA-2020

11-21 June 2020

25th Congress of the European Hematology Association, EHA-2020

Pagination

First page «
Previous page ‹
Page 29
Page 30
Page 31
Page 32
Current page 33
Page 34
Page 35
Page 36
Page 37
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel